Skip to content

Text · Comparison of two versions

Changes from plenary report to adopted text

A-9-2023-0290 → TA-9-2023-0364

From
A-9-2023-0290 Plenary report of 11 Oct 2023
To
TA-9-2023-0364 Adopted text of 17 Oct 2023
Changes
44 changes to the text
Paragraphs
+9 added · −20 removed · 41 changed
More facts (2)
Title (from)
on the proposal for a regulation of the European Parliament and of the Council establishing the Strategic Technologies for Europe Platform (‘STEP’) and amending Directive 2003/87/EC, Regulations (EU) 2021/1058, (EU) 2021/1056, (EU) 2021/1057, (EU) No 1303/2013, (EU) No 223/2014, (EU) 2021/1060, (EU) 2021/523, (EU) 2021/695, (EU) 2021/697 and (EU) 2021/241
Title (to)
Establishing the Strategic Technologies for Europe Platform (‘STEP’)

Every difference

The full paragraph comparison, packaging included; long runs of unchanged paragraphs are folded. One part of the text per page.

Part 5 of 5: Paragraphs 183–216

Regulation (EU) 2021/695

Change 35

ChangedArticle 17 – paragraph 1 – point -1b-1 a (new), Article 9 – paragraph 1 – subparagraph 2 – points b and c: (-1)(-1a) in Article 9(1), points (b) and (c) are replaced by the following: / ‘(b) autonomy, particularly for the implementation of equity support in order to ensure market-conform investment timelines as well as risk-taking as referred to in point (c); / (c) ability to take more risk than the market standards, particularly by providing patient investment to non-bankable innovations.’

6 unchanged paragraphs

Regulation (EU) 2021/695

Article 17 – paragraph 1 – point 1 – point a, Article 12 – paragraph 1: 1. The financial envelope for the implementation of the Programme for the period from 1 January 2021 to 31 December 2027 shall be EUR 87 423 000 000 in current prices for the specific programme referred to in point (a) of Article 1(2) and for the EIT and EUR 10 453 000 000 in current prices for the specific programme referred to in point (c) of Article 1(2).

Regulation (EU) 2021/695

Article 17 – paragraph 1 – point 1 – point b, Article 12 – paragraph 2 – point c: (b) in paragraph 2, point (c) is replaced by the following: / ‘(c) EUR 13 237 000 000 for Pillar III 'Innovative Europe' for the period 2021 to 2027, of which: / (i) EUR 10 052 000 000 for the EIC; / (ii) EUR 459 000 000 for European innovation ecosystems; / (iii) EUR 2 726 000 000 for the EIT;’ / (deleted) / (deleted) / (deleted) / (deleted) / (deleted) / (deleted) / (deleted) / (deleted)

Article 17 – paragraph 1 – point 3 – introductory part: (3) Article 48 is amended as follows:

Regulation (EU) 2021/695

Change 36

ChangedArticle 17 – paragraph 1 – point 3 – point a (new), Article 48 – paragraph 1– subparagraph 21 – point c: (3a)(a) in paragraph 1, second subparagraph, point (c) is replaced by the following: / ‘(c) equity-only support to non-bankable SMEs, including start-ups, carrying out breakthrough and disruptive non-bankable innovation may also be provided;’

Regulation (EU) 2021/695

Change 37

ChangedArticle 17 – paragraph 1 – point 3 – point b (new), Article 48 – paragraph 1 – subparagraph 2 – point d1 – point c:d: (3b)(b) in paragraph 1, second subparagraph, point (d) is added: / (d) equity-only support required for scale-up to non-bankable SMEs, including start-ups, and non-bankable small mid-caps, including entities which have already received support in line with points (a) to (c), carrying out breakthrough and disruptive non-bankable innovation in the technologies referred to in Article 2(1)(a) of Regulation .../... [STEP Regulation], financed under Article 3(b) of that Regulation.

Regulation (EU) 2021/695

Change 38

ChangedArticle 17 – paragraph 1 – point 3 – point c (new), Article 48 – paragraph 1 – subparagraph 3 a (new): (c) in paragraph 1, the following subparagraph is added :added: / ‘When providing equity support, the EIC shall strive to crowd-in other investors. However, in order to effectively support non-bankable innovation, equity support can be provided without crowding in other investors, particularly for but not limited to breakthrough and disruptive non-bankable innovation in the technologies referred to in Article 2(1)(a) of Regulation .../... [STEP Regulation].

Regulation (EU) 2021/695

Article 17 – paragraph 1 – point 3 – point d (new), Article 48 – paragraph 3: (d) paragraph 3 is replaced by the following: / ‘3. A single award decision, which shall be based on the outcome of the evaluation process referred to in paragraph 4 and in accordance with paragraph 8 shall cover and provide funding for all forms of Union contribution provided under EIC blended finance. The single award decision shall lead to a single contract covering all forms of Union contribution provided by the decision.’

Regulation (EU) 2021/695

Change 39

ChangedArticle 17 – paragraph 1 – point 3 – point e (new), Article 48 – paragraph 8:8 – subparagraph 1: (e) in paragraph 8, the first subparagraph is replaced by the following: / ‘For a proposal having passed the evaluation, the independent external experts referred to in paragraph 4 shall propose a corresponding Accelerator support, based on the risk incurred and the resources and time necessary to bring and deploy the innovation to the market. The Commission may reject, for justified reasons, a proposal retained by independent external experts, including due to non-compliance with the objectives of Union policies. The Programme Committee shall be informed of the reasons for such a rejection.’

10 unchanged paragraphs

Regulation (EU) 2021/695

Article 17 – paragraph 1 – point 3 – point f (new), Article 48 – paragraph 11 – subparagraph 1: (f) in paragraph 11, the first subparagraph is replaced by the following: / ‘The contract for the selected action, which shall comprise a single contract in accordance with paragraph 3, shall establish specific measurable milestones and the corresponding prefinancing and payments by instalments of the Accelerator support.’

Regulation (EU) 2021/695

Article 18 – paragraph 1 – point 1 – point a, Article 4 – paragraph 1: 1. In accordance with Article 12(1) of Regulation (EU) 2021/695, the financial envelope for the implementation of the Fund for the period from 1 January 2021 to 31 December 2027 shall be EUR 10 453 000 000 in current prices.

Regulation (EU) 2021/695

Article 18 – paragraph 1 – point 1 – point b, Article 4 – paragraph 2 – point a: (a) EUR 3 484 000 000 for research actions;

Regulation (EU) 2021/695

Article 18 – paragraph 1 – point 1 – point b, Article 4 – paragraph 2 – point b: (b) EUR 6 969 000 000 for development actions.

Regulation (EU) 2021/695

Article 18 – paragraph 1 – point 1 – point b, Article 4 – paragraph 5: (b) Paragraph 5 is added: / ‘An amount of EUR 2 500 000 in current prices of the amount referred to in paragraph 2 shall be allocated to calls for proposals or awards of funding supporting investments contributing to the STEP objectives referred to in Article 2(1), point (a)(i) of Regulation .../...11 [STEP Regulation].’

Change 40

ChangedRegulation (EU) 2021/5232021/241

Article 19 – paragraph 1 – point 1, Article 1 – paragraph 7: 3. Without prejudice to paragraph 2, Member States may also propose to include in their recovery and resilience plan, as estimated costs, the amount of the cash contribution for the purpose of the Member State compartment pursuant to the relevant provisions of the InvestEU Regulation exclusively for measures supporting investment operations contributing to the STEP objectives referred to in Article 2 of Regulation.../... 71 [STEP Regulation]. Those costs shall not exceed 6 % of the recovery and resilience plan’s total financial allocation, and the relevant measures, as set out in the recovery and resilience plan, shall respect the requirements of this Regulation. This limitation shall not apply to the cash contributions made pursuant to Article 33a.’

Change 41

ChangedRegulation (EU) 2021/5232021/241

Change 42

ChangedArticle 19 – paragraph 1 – point 2a, Article 1 – paragraph 33a: (2a) A new chapter is added: / ‘CHAPTER VIIa / EXCEPTIONAL USE OF RRF LOANS NOT REQUESTED BY MEMBER STATES / Article 33a / 1. The difference between the maximum amount available for loan support to Member States in accordance to article 6(1)(b) and the total amount requested by the Member States before 1 September 2023 shall be made available to all Member States for the implementation of investments contributing to the objectives referred to in Article 2 of Regulation .../... [STEP Regulation] through the Member State compartment of InvestEU. The maximum allocation for each Member State shall be made in accordance to the allocation key defined in Article 11 of this Regulation. / 2. Until 31 December 2023, upon request from a Member State, the Commission shall grant the Member State concerned a loan for the purpose referred to in paragraph 1. / 3. A Member State may request loan support until 15 December 2023 for the purpose referred to in paragraph 1. / 4. The Member State concerned shall use the proceeds of the loan to make a cash contribution to its Member State compartment of InvestEU to support objectives of the STEP, according to article 4(1) of Regulation (EU) 2021/523 [InvestEU Regulation].

Change 43

ChangedRegulation (EU) 2021/5232021/1755

Change 44

ChangedArticle 19a,19a (new), Article 4a: Article 19a / Amendments to Regulation (EU) 2021/1755 [BAR] / Regulation (EU) 2021/1755 is amended as follows: / Article 4a is amended as follows:replaced /by Articlethe 4afollowing: / Transfer to the Recovery and Resilience Facility, the European Regional Development Fund, the European Social Fund Plus or the Just Transition Fund / 1. By 1 March 2023, Member States may submit to the Commission a reasoned request to transfer to the Recovery and Resilience Facility established by Regulation (EU) 2021/241 of the European and of the Council all or part of the amounts of their provisional allocation set out in the implementing act of the Commission referred to in Article 4(5). If the transfer request is approved, the Commission shall amend the implementing act in order to reflect the adjusted amounts following the transfer. / 2.1a. By 30 September 2024, Member States may submit to the Commission a reasoned request to transfer to the European Regional Development Fund established by Regulation (EU) 2021/1058 of the European and of the Council, or the European Social Fund Plus established by Regulation (EU) 2021/1057 of the European Parliament and of the Council or the Just Transition Fund established by Regulation (EU) 2021/1056 of the European Parliament and of the Council all or part of the amounts of their provisional allocation set out in the implementing act of the Commission referred to in Article 4(5) for the purposes of supporting operations contributing to the STEP objectives referred to in Articl…Article 2 of Regu…

Annex: Annex / Definition of biotechnologies / (Article 2(1), point (a)(iii)) / Biotechnologies 1a means: / The application of science and technology to living organisms, as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge, goods and services. / The OECD list-based statistical definition of biotechnology contains: / DNA/RNA: Genomics, pharmacogenomics, gene probes, genetic engineering, DNA/RNA sequencing/synthesis/amplification, gene expression profiling, and use of antisense technology, large-scale DNA synthesis, genome- and gene-editing, gene drive. / Proteins and other molecules: Sequencing/synthesis/engineering of proteins and peptides (including large molecule hormones); improved delivery methods for large molecule drugs; proteomics, protein isolation and purification, signalling, identification of cell receptors. / Cell and tissue culture and engineering: Cell/tissue culture, tissue engineering (including tissue scaffolds and biomedical engineering), cellular fusion, vaccine/immune stimulants, embryo manipulation, marker assisted breeding technologies, metabolic engineering. / Process biotechnology techniques: Fermentation using bioreactors, biorefining, bioprocessing, bioleaching, biopulping, biobleaching, biodesulphurisation, bioremediation, biosensing, biofiltration and phytoremediation, molecular aquaculture. / Gene and RNA vectors: Gene therapy, viral vectors. / Bioinformatics: Construction of databases on…

Sources & citation

Where the facts on this page come from, and how to cite it.

Data source
Licensed CC BY 4.0.
Retrieved
28 September 2026

Cite as

European Parliament (2023). “Changes between A-9-2023-0290 and TA-9-2023-0364”. Text, 17 October 2023. from A-9-2023-0290, to TA-9-2023-0364. EU Parl Watch Research. https://news.eu-parl.st-solutions.dev/texts/A-9-2023-0290/compare/TA-9-2023-0364?all=1&part=5 (retrieved 28 September 2026). Data: European Parliament Open Data, https://data.europarl.europa.eu/ (CC BY 4.0).
BibTeX
@misc{epw-text-2023-10-17,
  author = {{European Parliament}},
  title = {{Changes between A-9-2023-0290 and TA-9-2023-0364}},
  year = {2023},
  date = {2023-10-17},
  howpublished = {\url{https://news.eu-parl.st-solutions.dev/texts/A-9-2023-0290/compare/TA-9-2023-0364?all=1&part=5}},
  url = {https://news.eu-parl.st-solutions.dev/texts/A-9-2023-0290/compare/TA-9-2023-0364?all=1&part=5},
  urldate = {2026-09-28},
  publisher = {EU Parl Watch Research},
  note = {Text. from A-9-2023-0290, to TA-9-2023-0364. Data: European Parliament Open Data (CC BY 4.0)}
}